RELEASE DATE:  April 2, 2003

NOTICE:  NOT-CA-03-017

National Cancer Institute (NCI)

In support of the National Cancer Institute objectives of Discovery, 
Development and Delivery, the Division of Cancer Treatment and 
Diagnosis (DCTD), has set apart funds in Fiscal Year 2003 specifically 
designated for studies of cancer in HIV+ populations and acquired 
immunodeficiency.   It is DCTD's intention to foster clinical and basic 
investigators to interact in a coordinated, complementary, or 
synergistic manner to conduct translational research in AIDS 
malignancies.  Investigators are encouraged to submit proposals for 
novel studies including but not limited to those that translate basic 
research findings into clinical application.  Approved projects will be 
supported by administrative supplementation.

The DCTD, NCI will provide NCI funded investigators conducting studies 
relevant to increasing our knowledge of the basic biology, pathogenic 
mechanisms, epidemiology, immunology, diagnosis, treatment, and 
prevention of cancer in the context of HIV/AIDS or other acquired 
immunodeficiency with supplemental funding for one year to conduct 
studies broadly related to a specific aim of the parent grant.  To 
stimulate studies whose results provide new insights and increase our 
understanding of the pathobiology of cancer in the context of acquired 
immunodeficiency and HIV/AIDS and to facilitate progress in developing 
treatment and prevention modalities for these cancers.   High risk, 
high impact studies not usually funded as traditional grants or 
exploratory projects in emerging areas of importance for malignancies 
in AIDS and other acquired immunodeficiencies are encouraged.  Studies 
may be based on recent observations or take advantage of new 
technologies.  Development of new methods or new technology is also 

Studies may include but are not limited to studies of the viral and 
cellular processes involved in development and maintenance of cancer, 
etiology, epidemiology and natural history, laboratory correlative 
studies, therapeutic target identification, drug development, animal 
models, pre-clinical and clinical studies, and registry development.  
Interdisciplinary studies, translational studies, and relationship 
building between basic and clinical investigators are encouraged.  

The PI must have an active NCI funded grant with at least one full year 
remaining at the time of anticipated funding (September 30, 2003).  
Funding is limited to one year with a total cost limit of $100,000.  PI 
salary support is not allowed. 


For additional information on this AIDS Malignancy Program Initiative 
see or contact:

Jodi B. Black, PhD
Program Director,
AIDS Malignancy Program
Division of Cancer Treatment and Diagnosis
(301) 402-6293

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.